These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23771003)

  • 1. Human herpes virus 6 reactivation: important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT.
    de Pagter PJ; Schuurman R; Keukens L; Schutten M; Cornelissen JJ; van Baarle D; Fries E; Sanders EA; Minnema MC; van der Holt BR; Meijer E; Boelens JJ
    Bone Marrow Transplant; 2013 Nov; 48(11):1460-4. PubMed ID: 23771003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome.
    de Pagter PJ; Schuurman R; Visscher H; de Vos M; Bierings M; van Loon AM; Uiterwaal CS; van Baarle D; Sanders EA; Boelens J
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):831-9. PubMed ID: 18541204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study.
    Dulery R; Salleron J; Dewilde A; Rossignol J; Boyle EM; Gay J; de Berranger E; Coiteux V; Jouet JP; Duhamel A; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1080-9. PubMed ID: 22212513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease.
    Gotoh M; Yoshizawa S; Katagiri S; Suguro T; Asano M; Kitahara T; Akahane D; Okabe S; Tauchi T; Ito Y; Ohyashiki K
    Transpl Infect Dis; 2014 Jun; 16(3):440-9. PubMed ID: 24810656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First analysis of human herpesvirus 6T-cell responses: specific boosting after HHV6 reactivation in stem cell transplantation recipients.
    de Pagter AP; Boelens JJ; Scherrenburg J; Vroom-de Blank T; Tesselaar K; Nanlohy N; Sanders EA; Schuurman R; van Baarle D
    Clin Immunol; 2012 Sep; 144(3):179-89. PubMed ID: 22820131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for human herpesvirus 6 reactivation and its relationship with syndrome of inappropriate antidiuretic hormone secretion after stem cell transplantation in pediatric patients.
    Toriumi N; Kobayashi R; Yoshida M; Iguchi A; Sarashina T; Okubo H; Suzuki D; Sano H; Ogata M; Azuma H
    J Pediatr Hematol Oncol; 2014 Jul; 36(5):379-83. PubMed ID: 23929317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Human Herpesvirus-6 Reactivation on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation.
    Aoki J; Numata A; Yamamoto E; Fujii E; Tanaka M; Kanamori H
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2017-22. PubMed ID: 26226409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of human herpesvirus 6B reactivation on early complications following allogeneic hematopoietic stem cell transplantation.
    Wang LR; Dong LJ; Zhang MJ; Lu DP
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1031-7. PubMed ID: 17067909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterizing human herpes virus 6 following hematopoietic stem cell transplantation.
    Perissinotti AJ; Gulbis A; Shpall EJ; Howell J
    J Oncol Pharm Pract; 2015 Apr; 21(2):85-92. PubMed ID: 24407957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human herpesvirus 6 (HHV-6) reactivation and HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: a multicenter, prospective study.
    Ogata M; Satou T; Kadota J; Saito N; Yoshida T; Okumura H; Ueki T; Nagafuji K; Kako S; Uoshima N; Tsudo M; Itamura H; Fukuda T
    Clin Infect Dis; 2013 Sep; 57(5):671-81. PubMed ID: 23723198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation.
    Peric Z; Cahu X; Chevallier P; Brissot E; Malard F; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Milpied N; Coste-Burel M; Imbert-Marcille BM; Mohty M
    Leukemia; 2011 Jun; 25(6):932-8. PubMed ID: 21350556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human herpesvirus 6 infection after allogeneic stem cell transplantation: incidence, outcome, and factors associated with HHV-6 reactivation.
    Jeulin H; Agrinier N; Guery M; Salmon A; Clément L; Bordigoni P; Venard V
    Transplantation; 2013 May; 95(10):1292-8. PubMed ID: 23514960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactivation of Human Herpes Virus-6 After Pediatric Stem Cell Transplantation: Risk Factors, Onset, Clinical Symptoms and Association With Severity of Acute Graft-Versus-Host Disease.
    Verhoeven DH; Claas EC; Jol-van der Zijde CM; Thijssen JC; Lankester AC; Bredius RG; Putter H; Kroes AC; Egeler RM; Schilham MW; van Tol MJ
    Pediatr Infect Dis J; 2015 Oct; 34(10):1118-27. PubMed ID: 26132825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning.
    Kalpoe JS; van der Heiden PL; Barge RM; Houtzager S; Lankester AC; van Tol MJ; Kroes AC
    Eur J Haematol; 2007 Apr; 78(4):314-21. PubMed ID: 17331130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivations of cytomegalovirus, human herpes virus 6, and Epstein-Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation.
    Jaskula E; Dlubek D; Sedzimirska M; Duda D; Tarnowska A; Lange A
    Transplant Proc; 2010 Oct; 42(8):3273-6. PubMed ID: 20970670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations of human herpesvirus 6B and CMV infection with acute GVHD in recipients of allogeneic haematopoietic stem cell transplantation.
    Wang LR; Dong LJ; Zhang MJ; Lu DP
    Bone Marrow Transplant; 2008 Nov; 42(10):673-7. PubMed ID: 18695666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Foscarnet against human herpesvirus (HHV)-6 reactivation after allo-SCT: breakthrough HHV-6 encephalitis following antiviral prophylaxis.
    Ogata M; Satou T; Inoue Y; Takano K; Ikebe T; Ando T; Ikewaki J; Kohno K; Nishida A; Saburi M; Miyazaki Y; Ohtsuka E; Saburi Y; Fukuda T; Kadota J
    Bone Marrow Transplant; 2013 Feb; 48(2):257-64. PubMed ID: 22750998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation.
    Admiraal R; de Koning CCH; Lindemans CA; Bierings MB; Wensing AMJ; Versluys AB; Wolfs TFW; Nierkens S; Boelens JJ
    J Allergy Clin Immunol; 2017 Dec; 140(6):1643-1650.e9. PubMed ID: 28392330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.